Diligence memo · auto-generated · as of July 2, 2026
Catalent, Inc.
Catalent, Inc. has raised $650M over 1 round; too few niche peers to rank its valuation yet.
Businessfiled
Catalent, Inc. operates in Pharmaceuticals, based in Somerset. Catalent delivers end-to-end pharma solutions as a trusted CDMO, advancing drug development and manufacturing worldwide. Partner with us today!
Sub-sector tags: biotech, pharma.
Capital & rounds (filed)filed
Catalent, Inc. has raised $650M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Growth/Late (a round over $400M).
Largest single filing: $650M on 2019-05-17.
Most recent recorded round closed around 2019-05-17.
Valuation (modeled)modeled
Provath models Catalent, Inc. at approximately $23.6B (range $4.3B–$42.5B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Last raise 7.1 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 100% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 100% of those peers.
Closest niche peers: Sage Therapeutics, Inc., Lyell Immunopharma, Inc..
Peoplefiled
14 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.